

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI GIULIO A. DeCONTI, Jr., Esq. ELIZABETH A. HANLEY AMY BAKER MANDRAGOURAS ANTHONY A LAURENTANO KEVIN J. CANNING JANE E. REMILLARD DEANNE SMITH DEBRA J. MILASINCIC, Ph.D. WILLIAM A. SCOFIELD, Jr. SIBLEY P. REPPERT DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER MEGAN E. WILLIAMS, Ph.D. LISA DIROCCO TYNER HATHAWAY P. RUSSELL * MARIA LACCOTRIPE ZACHARAKIS, Ph.D. MERIDETH C. ARNOLD

DANIELLE L. HERRITT
EU:HOON LEE "
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. DAOTAN, CI.D.
CHRISTOPHER J. MCKENNA
VINCENT P. LOCCISANO
JAMES M. MCKENZIE

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS

JONATHAN M. SPARKS, Ph.I.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL A. MELLO, Ph.D.
JAMES H. VELEMA
CHRISTOPHER E. DRABIK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
A. JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
CYNTHIA M. GILBERT
MEAGHAN L. RICHMOND, Ph.D.

- Admitted in TX only
- ** Admitted in CT only

November 9, 2004

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

lc@lahive.com

U.S. Patent Application No.: 10/770,883

For: REDUCING TETRACYCLINE RESISTANCE IN LIVING CELLS

Inventor: Levy, Stuart B. Filed: February 2, 2004

Our Ref. No.: PKZ-012CPCN4

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Information Disclosure Statement;
- 2. PTO Form SB/08; and
- 3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:

November 8, 2004

Cynthia M. Sorops, Registration No. 53,623

Respectfully submitted,

LAHIYE & COCKFIELD, LLP

Cynthia M. Soroos

Registration No. 53,623

Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Levy, Stuart B.

Serial No.: 10/770,883

Filed: February 2, 2004

For: REDUCING TETRACYCLINE RESISTANCE IN

LIVING CELLS

Attorney Docket No.: PKZ-012CPCN4

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Group Art Unit: 1614

Examiner: Not Yet Assigned

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

November 9, 2004

Date of Signature and of Mail Deposit

By:

Cynthia M. Soroos

Registration No. 53,623

Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

For the Examiner's convenience in reviewing this continuation application, Applicant submits a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. The present application is a Continuation of U.S. Serial No.09/504,897, filed February 16, 2000 (Atty. Docket No. PKZ-012CPCN3). All references listed on the enclosed PTO Form SB/08 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of the references are not enclosed but will be provided upon request.

Serial Number: 10/770,883 Page -2- Group Art Unit: 1614

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. <u>If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement</u>, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Cynthia M. Soroos

Registration No. 53,623 Attorney for Applicant

28 State Street Boston, MA 02109 (617) 227-7400

Date: November 9, 2004

CMS/MEW/EAH/rl

Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE duction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/PT	0		Complete if Known		
				Application Number	10/770,883	
IN.	IFORMATION	I DI	SCLOSURE	Filing Date	February 2, 2004	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Levy, Stuart B.	
				Art Unit	1614	
	(Use as many sho	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet 1 of 2		Attorney Docket Number	PKZ-012CPCN4			

	U.S. PATENT DOCUMENTS							
Examiner	a.,	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
Initials*	Cite No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document				
	A1	3,236,736	02-1966	Fitch, et al.				
	A2	3,454,697	07-1969	Joyner, et al.	-			
	A3	3,579,564	05-1971	Blackwood, et al.				
	A4	3,863,009	01-1975	Johnston				
	A5	4,024,272	05-17-1977	Rogalski, W., et al.				
	A6	4,126,680	11-21-1978	Armstrong, W.W.				
	A7	4,806,529	02-21-1989	Levy, S.B.				
	A8	5,021,407	06-04-1991	Levy, S.B.				
	A9	5,064,821	11-12-1991	Levy, S.B.				
	A10	5,258,372	03-02-1991	Levy, S.B.				
	A11	5,589,470	12-31-1996	Levy, S.B.				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	A12	WO 84/01895 A1	05-24-1984	Tufts University				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	A13	Bernardi, L., et al., "Tetracycline derivatives I. Esters of 5-oxytetracyclines: chemistry and biological activity." Il Farmaco – Ed. Sci. 1974 Dec; 29(12):902-9.					
	A14	Brock, P.G., et al., "Comparison of the in vitro serum microbiological activity of a triple tetracycline tablet, 300 mg B.I.D. with oxytetracyline, 250 mg Q.I.D." J Int Med Res. 1981; 9(5):360-4.					
	A15	Candanaza, et al., Chem Abst. 83:1393f.	1				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/PT	o		Complete if Known		
				Application Number	10/770,883	
IN	IFORMATION	I DI	SCLOSURE	Filing Date	February 2, 2004	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Levy, Stuart B.	
				Art Unit	1614	
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	PKZ-012CPCN4	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	B1	Chopra, I., et al., "The tetracyclines: prospects at the beginning of the 1980s." J Antimicrob Chemother. 1981 Jul; 8(1):5-21.					
	B2	Connamacher, R.H., et al., Chem Abst. 89: 71494n (1978).					
	В3	Curiale, M.S., et al., "Two complementation groups mediate tetracycline resistance determined by Tn10." J Bacteriol. 1982 Jul; 151(1):209-15.					
	B4	Grassi, et al., New Trends in Antibiotics: Res. & Therapy, 3-55 (1981).					
	B5	Korolkovas, A., et al., Essentials of Medicinal Chem. 512-7 (1976).					
	B6	Kuck, et al., Chem Abst. 74: 74941g (1971).					
	B7	Kuck, et al., Chem Abst. 79: 74181n (1973).					
	B8	Lebek, et al., Chem Abst. 82: 26560a (1974).					
	В9	Lehninger, Biochemistry - The Molecular Basis of Cell Structure and Function, 941 (1975).					
	B10	Leigh, et al., Chem Abst. 81: 115200e (1974).					
	B11	Levy, S.B., New Trends in Antibiotics: Res. and Therapy, 27-44 (1981).					
	B12	Levy, S.B., et al., Biochemical and Biophysical Res. Commun. 56(4): 1060-8 (1974).					
	B13	Levy, S.B., et al., Nature 275(5683): 90-2 (1978).					
	B14	McMurry, L., et al., "Two transport systems for tetracycline in sensitive Escherichia coli: critical role for an initial rapid uptake system insensitive to energy inhibitors." Antimicrob Agents Chemother. 1978 Aug; 14(2):201-9.					
	B15	McMurry, L., et al., "Active uptake of tetracycline by membrane vesicles from susceptible Escherichia coli." Antimicrob Agents Chemother. 1981 Sep; 20(3):307-13.					
	B16	McMurry, L., et al., "Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli." <i>Proc Natl Acad Sci USA</i> . 1980 Jul; 77(7):3974-7.					
	B17	Mendez, B., et al., "Heterogeneity of tetracycline resistance determinants." <i>Plasmid.</i> 1980 Mar; 3(2):99-108.					
	B18	Samra, et al., Chem Abst. 90: 198211u (1978).					
	B19	Sompolinsky, et al., Chem Abst. 79: 143198n (1973).					
	B20	Williams, et al., Chem Abst. 86: 150977p.					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Consider	red

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.